New anticoagulant drugs among elderly patients is caution necessary?

Archives of Internal Medicine

Volumn 171, Issue 14, 2011, Pages 1287-1288

  Jacobs, Jeremy M ^a   Stessman, Jochanan ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN; DABIGATRAN ETEXILATE; WARFARIN;

ANTICOAGULATION; BLEEDING; BLEEDING TIME; DRUG FATALITY; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; NOTE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; STROKE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; PYRIDINES; RISK FACTORS; STROKE;

EID: 79960965512     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.308     Document Type: Note

References (10)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
2. Wallentin L, Yusuf S, Ezekowitz MD, et al RE-LY Investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975-983.
3. Escobar C, Barrios V, Jimenez D. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants? Cardiovasc Ther. 2010;28(5):295-301.
4. Sellers MB, Newby LK. Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J. 2011;161(2):241-246.
5. Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118(6):612-617. (Pubitemid 40732700)
6. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med. 2011;171(14):1285-1286.
7. Giannelli SV, Patel KV, Windham BG, Pizzarelli F, Ferrucci L, Guralnik JM. Magnitude of underascertainment of impaired kidney function in older adults with normal serum creatinine. J Am Geriatr Soc. 2007;55(6):816-823. (Pubitemid 47011053)
8. Boehringer Ingelheim. Pradaxa (dabigatran etexilate): advisory committee briefing document. August 27, 2010. http://www.fda.gov/downloads /AdvisoryCommittees/CommitteesMeetingMaterials/Drugs / CardiovascularandRenalDrugsAdvisoryCommittee/UCM247244.pdf. Accessed March 2011.
9. Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004;351 (27):2870-2874.
10. Fried TR, Tinetti ME, Towle V, O'Leary JR, Iannone L. Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention [published online February 28, 2011]. Arch Intern Med. doi:10.1001/archinternmed.2011.32.